Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Asset Writedowns and Impairment: 2022-2025

Historic Asset Writedowns and Impairment for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $2,424.

  • InMed Pharmaceuticals' Asset Writedowns and Impairment rose 115.83% to $42,408 in Q2 2024 from the same period last year, while for Jun 2024 it was $37,977, marking a year-over-year change of. This contributed to the annual value of $2,424 for FY2025, which is 99.21% down from last year.
  • InMed Pharmaceuticals' Asset Writedowns and Impairment amounted to $2,424 in FY2025, which was down 99.21% from $305,812 recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Asset Writedowns and Impairment high stood at $3.5 million for FY2022, and its period low was $2,424 during FY2025.
  • In the last 3 years, InMed Pharmaceuticals' Asset Writedowns and Impairment had a median value of $305,812 in 2024 and averaged $205,724.
  • Data for InMed Pharmaceuticals' Asset Writedowns and Impairment shows a maximum YoY plummeted of 99.21% (in 2025) over the last 5 years.
  • InMed Pharmaceuticals' Asset Writedowns and Impairment (Yearly) stood at $3.5 million in 2022, then crashed by 91.10% to $308,937 in 2023, then dropped by 1.01% to $305,812 in 2024, then slumped by 99.21% to $2,424 in 2025.